Skip to content
Enoxacin
Penetrex (enoxacin) is a small molecule pharmaceutical. Enoxacin was first approved as Penetrex on 1991-12-31. It is used to treat escherichia coli infections, gonorrhea, haemophilus infections, klebsiella infections, and proteus infections amongst others in the USA. It is known to target V-type proton ATPase subunit B, brain isoform.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Enoxacin
Tradename
Company
Number
Date
Products
PENETREXSanofiN-019616 DISCN1991-12-31
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
penetrex(r) arthritis pain reliefunapproved drug other2022-06-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
escherichia coli infectionsEFO_1001318D004927B96.20
gonorrheaDOID_7551D006069A54
haemophilus infectionsEFO_1001127D006192
klebsiella infectionsEFO_1001353D007710
proteus infectionsEFO_1001130D011512
pseudomonas infectionsEFO_0001076D011552
staphylococcal infectionsD013203A49.01
urinary tract infectionsEFO_0003103D014552N39.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J01: Antibacterials for systemic use
J01M: Quinolone antibacterials
J01MA: Fluoroquinolone antibacterials, systemic
J01MA04: Enoxacin
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.013121123
Myelodysplastic syndromesD009190D462417
Myeloid leukemiaD007951C921112
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelomonocytic leukemia chronicD015477C93.1235
Hematologic neoplasmsD019337212
Multiple myelomaD009101C90.0212
NeoplasmsD009369C80222
Biphenotypic leukemia acuteD015456C95.011
GliomaD005910EFO_0000520111
CholangiocarcinomaD018281C22.1111
ChondrosarcomaD002813111
LeukemiaD007938C95111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients44
Hepatic insufficiencyD04855022
Prostatic neoplasmsD011471C6111
Castration-resistant prostatic neoplasmsD06412911
Breast neoplasmsD001943EFO_0003869C5011
Pancreatic neoplasmsD010190EFO_0003860C2511
Non-hodgkin lymphomaD008228C85.911
Primary myelofibrosisD055728D47.411
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.011
B-cell chronic lymphocytic leukemiaD015451C91.111
Show 7 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameENOXACIN
INNenoxacin
Description
Enoxacin is a 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea. It has a role as an antibacterial drug and a DNA synthesis inhibitor. It is a monocarboxylic acid, an amino acid, a 1,8-naphthyridine derivative, a N-arylpiperazine, a quinolone antibiotic and a fluoroquinolone antibiotic.
Classification
Small molecule
Drug classantibacterials (quinolone derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21
Identifiers
PDB
CAS-ID74011-58-8
RxCUI3925
ChEMBL IDCHEMBL826
ChEBI ID157175
PubChem CID3229
DrugBankDB00467
UNII ID325OGW249P (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ATP6V1B2
ATP6V1B2
Organism
Homo sapiens
Gene name
ATP6V1B2
Gene synonyms
ATP6B2, VPP3
NCBI Gene ID
Protein name
V-type proton ATPase subunit B, brain isoform
Protein synonyms
ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2, Endomembrane proton pump 58 kDa subunit, H+ transporting two-sector ATPase, HO57, testicular secretory protein Li 65, V-ATPase B2 subunit, V-ATPase subunit B 2, vacuolar H+-ATPase 56,000 subunit, Vacuolar proton pump subunit B 2
Uniprot ID
Mouse ortholog
Atp6v1b2 (11966)
V-type proton ATPase subunit B, brain isoform (Q3UAW7)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,936 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,268 adverse events reported
View more details